Thirdly, the data highlight the safety of targeting PR1 in hematologic malignancies, an observation that is highly significant for the future of PR1- targeting approaches since the PR1 epitope is expressed by normal hematopoietic cells, although at a much lower level [ 8 ].
1
—
—